Perioperative adebrelimab for locally advanced cervical cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a drug called adebrelimab, given before and after standard treatment for locally advanced cervical cancer. The goal is to see if adding this immunotherapy can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of cervical cancer called squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma, and your tumor is at least 4 cm in size.
- Your cancer is at a stage (IB3, IIA2, or certain IIB/IIIC1r) where surgery is planned, and you have not yet had radiation, chemotherapy, or other cancer treatment for it.
- You are generally healthy (able to do light activity) and have good organ function (kidneys, liver, blood counts).
- You must be HPV-positive and have a tumor that can be measured on a CT scan.
- You cannot have an autoimmune disease, HIV, hepatitis, or have had prior treatment with immune checkpoint inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a combination of immunotherapy (zimberelimab) and chemotherapy before surgery for locally advanced cervical cancer that has not spread far. It aims to shrink the tumor to make surgery more effective.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy before surgery for locally advanced cervical cancer. It aims to shrink tumors and improve outcomes for patients who haven't had prior systemic treatment.
This trial tests a new combination of short-course radiation, an immunotherapy drug called adebrelimab, and standard chemotherapy before surgery for locally advanced cervical cancer. It aims to see if this approach can shrink tumors more effectively.
This trial is testing a new immunotherapy drug (adebrelimab) given along with standard chemoradiation for advanced cervical cancer. The goal is to see if adding this drug improves treatment effectiveness.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemoradiation helps treat locally advanced cervical cancer better than chemoradiation alone.
Hear when a new Locally Advanced Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.